利用树状数据挖掘在疫苗安全数据链中广泛评估COVID-19疫苗安全性
研究利用树状数据挖掘方法,在疫苗安全数据链中广泛筛查辉瑞-BioNTech、Moderna和Janssen COVID-19疫苗接种后的不良事件。辉瑞-BioNTech接种后检测到未特指不良反应、常见疫苗反应、心肌炎/心包炎等聚集信号,Moderna结果相似但无显著心肌炎/心包炎聚集,Janssen接种后检测到步态/移动异常和肌无力聚集,后者被认为与一个研究中心的实践相关混杂。
要点
- 辉瑞-BioNTech接种后检测到未特指不良反应、常见疫苗反应、心肌炎/心包炎等聚集信号
- Moderna结果与辉瑞-BioNTech相似,但未检测到显著的心肌炎/心包炎聚集信号
- Janssen接种后检测到步态/移动异常和肌无力聚集,被认为与一个研究中心的实践相关混杂
核心结论
- 辉瑞-BioNTech接种后检测到未特指不良反应、常见疫苗反应、胸痛和心悸以及第二剂后心肌炎/心包炎的聚集信号。
- 这种数据挖掘的独特优势在于其非靶向性以及对诊断和风险区间多重性的内在调整。
研究设计与样本
- 研究采用自身对照树-时间扫描统计量及TreeScan软件进行树状数据挖掘。
- 疫苗安全数据链中2020-2021年接种至少1剂COVID-19疫苗的入组者,辉瑞-BioNTech或Moderna接种后随访70天,Janssen接种后随访56天。
- 对住院或急诊环境中的新发诊断,在ICD-10-CM层级代码结构和接种后随访期内分析聚集性。
- 使用蒙特卡洛模拟估计p值,p=0.01为预先设定的聚集统计学显著性界值。
主要发现
- 辉瑞-BioNTech接种后聚集包括:未特指不良反应;常见疫苗反应如发热、肌痛和头痛;心肌炎/心包炎;以及较不特异的心脏或呼吸道症状,最强聚集通常出现在第2剂后;还有第1剂后前3周内的COVID-19/病毒性肺炎/脓毒症/呼吸衰竭。
- Moderna结果相似,但无显著的心肌炎/心包炎聚集。
- 进一步调查提示第五组信号是mRNA疫苗第1剂后3周有效性的表现。
- Janssen接种者检测到未特指或常见疫苗反应、步态/移动异常和肌无力的聚集;后两者被认为源自一个研究中心实践相关的混杂。
关键数值与推荐
- 辉瑞-BioNTech、Moderna和Janssen疫苗接种者分别有4.1、2.6和0.4百万。
- 辉瑞-BioNTech或Moderna接种后随访70天,Janssen接种后随访56天。
- 聚集统计学显著性界值为p=0.01。
局限性
- Janssen接种者中步态/移动异常和肌无力的聚集被认为源自一个研究中心实践相关的混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Except for spontaneous reporting systems, vaccine safety monitoring generally involves pre-specifying health outcomes and post-vaccination risk windows of concern. Instead, we used tree-based data-mining to look more broadly for possible adverse events after Pfizer-BioNTech, Moderna, and Janssen COVID-19 vaccination. METHODS: Vaccine Safety Datalink enrollees receiving ≥1 dose of COVID-19 vaccine in 2020-2021 were followed for 70 days after Pfizer-BioNTech or Moderna and 56 days after Janssen vaccination. Incident diagnoses in inpatient or emergency department settings were analyzed for clustering within both the hierarchical ICD-10-CM code structure and the post-vaccination follow-up period. We used the self-controlled tree-temporal scan statistic and TreeScan software. Monte Carlo simulation was used to estimate p-values; p = 0.01 was the pre-specified cut-off for statistical significance of a cluster. RESULTS: There were 4.1, 2.6, and 0.4 million Pfizer-BioNTech, Moderna, and Janssen vaccinees, respectively. Clusters after Pfizer-BioNTech vaccination included: (1) unspecified adverse effects, (2) common vaccine reactions, such as fever, myalgia, and headache, (3) myocarditis/pericarditis, and (4) less specific cardiac or respiratory symptoms, all with the strongest clusters generally after Dose 2; and (5) COVID-19/viral pneumonia/sepsis/respiratory failure in the first 3 weeks after Dose 1. Moderna results were similar but without a significant myocarditis/pericarditis cluster. Further investigation suggested the fifth signal group was a manifestation of mRNA vaccine effectiveness after the first 3 weeks. Janssen vaccinees had clusters of unspecified or common vaccine reactions, gait/mobility abnormalities, and muscle weakness. The latter two were deemed to have arisen from confounding related to practices at one site. CONCLUSIONS: We detected post-vaccination clusters of unspecified adverse effects, common vaccine reactions, and, for the mRNA vaccines, chest pain and palpitations, as well as myocarditis/pericarditis after Pfizer-BioNTech Dose 2. Unique advantages of this data mining are its untargeted nature and its inherent adjustment for the multiplicity of diagnoses and risk intervals scanned.
引用
- Yih WK, Daley MF, Duffy J, et al. A broad assessment of covid-19 vaccine safety using tree-based data-mining in the vaccine safety datalink. Vaccine. 2022. PMID: 36535825. doi:10.1016/j.vaccine.2022.12.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。